A detailed history of Amalgamated Bank transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 979 shares of TARS stock, worth $45,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares
979
Previous 979 -0.0%
Holding current value
$45,670
Previous $27,000 18.52%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$19.61 - $39.22 $28,787 - $57,574
-1,468 Reduced 59.99%
979 $36,000
Q4 2023

Feb 06, 2024

BUY
$12.98 - $20.73 $2,115 - $3,378
163 Added 7.14%
2,447 $50,000
Q3 2023

Nov 08, 2023

BUY
$14.75 - $24.62 $5,811 - $9,700
394 Added 20.85%
2,284 $41,000
Q1 2023

May 02, 2023

SELL
$11.92 - $16.27 $4,827 - $6,589
-405 Reduced 17.65%
1,890 $24,000
Q2 2022

Aug 15, 2022

BUY
$11.08 - $19.08 $10,958 - $18,870
989 Added 75.73%
2,295 $34,000
Q1 2022

Jun 30, 2022

BUY
$14.49 - $24.28 $18,923 - $31,709
1,306 New
1,306 $22,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.24B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.